Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 studyMilind Javle, Ghassan K. Abou‐Alfa, Dirk‐Thomas Waldschmidt et al.|The Lancet. Gastroenterology & hepatology|2021Cited by 423
Infigratinib in patients with advanced cholangiocarcinoma with <i>FGFR2</i> gene fusions/translocations: the PROOF 301 trialShalini Makawita, Milind Javle, Ghassan K. Abou‐Alfa et al.|Future Oncology|2020Cited by 91
Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an <i>FGFR2</i> gene fusion or rearrangement.Milind Javle, Ghassan K. Abou‐Alfa, Sameek Roychowdhury et al.|Journal of Clinical Oncology|2021Cited by 86